Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy
© 2021 The Authors..
CRISPR/Cas9-based gene editing has emerged as a powerful biotechnological tool, that relies on Cas9 protein and single guided RNA (sgRNA) to edit target DNA. However, the lack of safe and efficient delivery carrier is one of the crucial factors restricting its clinical transformation. Here, we report an ionizable lipid nanoparticle (iLP181, pKa = 6.43) based on iLY1809 lipid enabling robust gene editing in vitro and in vivo. The iLP181 effectively encapsulate psgPLK1, the best-performing plasmid expressing for both Cas9 protein and sgRNA targeting Polo-like kinase 1 (PLK1). The iLP181/psgPLK1 nanoformulation showed uniformity in size, regular nanostructure and nearly neutral zeta potential at pH 7.4. The nanoformulation effectively triggered editing of PLK1 gene with more than 30% efficiency in HepG2-Luc cells. iLP181/psgPLK1 significantly accumulated in the tumor for more than 5 days after a single intravenous injection. In addition, it also achieved excellent tumor growth suppression compared to other nucleic acid modalities such as siRNA, without inducing adverse effects to the main organs including the liver and kidneys. This study not only provides a clinically-applicable lipid nanocarrier for delivering CRISPR/Cas system (even other bioactive molecules), but also constitutes a potential cancer treatment regimen base on DNA editing of oncogenes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Bioactive materials - 9(2022) vom: 17. März, Seite 590-601 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Chunhui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CRISPR/Cas |
|---|
| Anmerkungen: |
Date Revised 08.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.bioactmat.2021.05.051 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333906799 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333906799 | ||
| 003 | DE-627 | ||
| 005 | 20231225222617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bioactmat.2021.05.051 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333906799 | ||
| 035 | |a (NLM)34853819 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Chunhui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. | ||
| 520 | |a CRISPR/Cas9-based gene editing has emerged as a powerful biotechnological tool, that relies on Cas9 protein and single guided RNA (sgRNA) to edit target DNA. However, the lack of safe and efficient delivery carrier is one of the crucial factors restricting its clinical transformation. Here, we report an ionizable lipid nanoparticle (iLP181, pKa = 6.43) based on iLY1809 lipid enabling robust gene editing in vitro and in vivo. The iLP181 effectively encapsulate psgPLK1, the best-performing plasmid expressing for both Cas9 protein and sgRNA targeting Polo-like kinase 1 (PLK1). The iLP181/psgPLK1 nanoformulation showed uniformity in size, regular nanostructure and nearly neutral zeta potential at pH 7.4. The nanoformulation effectively triggered editing of PLK1 gene with more than 30% efficiency in HepG2-Luc cells. iLP181/psgPLK1 significantly accumulated in the tumor for more than 5 days after a single intravenous injection. In addition, it also achieved excellent tumor growth suppression compared to other nucleic acid modalities such as siRNA, without inducing adverse effects to the main organs including the liver and kidneys. This study not only provides a clinically-applicable lipid nanocarrier for delivering CRISPR/Cas system (even other bioactive molecules), but also constitutes a potential cancer treatment regimen base on DNA editing of oncogenes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CRISPR/Cas | |
| 650 | 4 | |a Cancer therapy | |
| 650 | 4 | |a Gene editing | |
| 650 | 4 | |a Lipid nanoparticle | |
| 650 | 4 | |a PLK1 | |
| 700 | 1 | |a Yang, Tongren |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Yuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mengjie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Deyao |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Wanxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaoxia |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Abid |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Xing-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yuanyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioactive materials |d 2016 |g 9(2022) vom: 17. März, Seite 590-601 |w (DE-627)NLM270377816 |x 2452-199X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g day:17 |g month:03 |g pages:590-601 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bioactmat.2021.05.051 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |b 17 |c 03 |h 590-601 | ||